Ascendiant Capital Markets initiates coverage on StemCells (STEM +1.7% to $2.44) with a "Buy"...

|By:, SA News Editor

Ascendiant Capital Markets initiates coverage on StemCells (STEM +1.7% to $2.44) with a "Buy" recommendation and a price target of $2.60. "We believe that StemCells is an intriguing speculative small cap investment story," Ascendiant writes. "The Company is breaking new ground in its development of novel stem cell therapies."